The Impact of Music Intervention on Sleep

Sponsor
Rutgers, The State University of New Jersey (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06088810
Collaborator
National Institute on Aging (NIA) (NIH)
144
2
26

Study Details

Study Description

Brief Summary

The primary purpose of this Stage 1b NIH-funded clinical trial (K23AG073618, PI Petrovsky) is to determine the efficacy of a 1-month music intervention (Calming Music Personalized for Sleep Enhancement in PeRsons living with Dementia, CoMPoSER) on health outcomes in 72 dyads (144 participants) of persons living with dementia (PLWD) and their caregivers (Stage 1b). The secondary purpose of this research project is to examine the mechanism of stress reduction and sustained effects of the music intervention on PLWD and caregiver well-being. We will evaluate the acceptability of the mobile application CoMPoSER in a pilot RCT and determine the impact of the mobile application CoMPoSER on PLWD (sleep latency, sleep efficiency, wake after sleep onset, total sleep time, sleep quality) and caregiver (perceived stress and well-being) outcomes.

Condition or Disease Intervention/Treatment Phase
  • Other: CoMPoSER intervention group
  • Other: Sleep Education
N/A

Detailed Description

Aim 1: Evaluate the acceptability of the mobile application CoMPoSER in a pilot RCT.

Aim 2: Determine the impact of the mobile application CoMPoSER on PLWD (sleep latency, sleep efficiency, wake after sleep onset, total sleep time, sleep quality) and caregiver (perceived stress and well-being) outcomes.

Aim 3: Examine stress reduction as a mechanism of action measured via salivary cortisol by which 1-month long CoMPoSER intervention affects insomnia symptoms in PLWD.

Aim 4: To determine the sustained (3 months) efficacy of CoMPoSER compared to control group on PLWD and caregiver health outcomes.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study will consist of 144 participants (72 dyads). Dyads will receive 4 weekly phone calls in addition to the baseline and post-intervention in-person home visits. Those receiving the CoMPoSER intervention will undergo the following components: A) relaxation techniques; B) meaningful and relaxing music playlist, tailored to PLWD preferred genre, and C) nighttime routine guidance. Those undergoing the attention control intervention will receive sleep education. The attention control design includes participants finding their own treatment if assigned to no-treatment group and higher study dropout rates.The study will consist of 144 participants (72 dyads). Dyads will receive 4 weekly phone calls in addition to the baseline and post-intervention in-person home visits. Those receiving the CoMPoSER intervention will undergo the following components: A) relaxation techniques; B) meaningful and relaxing music playlist, tailored to PLWD preferred genre, and C) nighttime routine guidance. Those undergoing the attention control intervention will receive sleep education. The attention control design includes participants finding their own treatment if assigned to no-treatment group and higher study dropout rates.
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Impact of Music Intervention on Sleep: CoMPoSER Trial
Anticipated Study Start Date :
Jun 1, 2024
Anticipated Primary Completion Date :
Aug 1, 2026
Anticipated Study Completion Date :
Aug 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Sleep Education Group

Participants in this group will receive sleep education.

Other: Sleep Education
Participants in this intervention will receive sleep education based on the NIH/NIA guide, which includes tips for getting a good night's sleep.

Experimental: CoMPoSER Intervention Group

Participants in this group will use a mobile application that plays calming music personalized for sleep enhancement.

Other: CoMPoSER intervention group
Participants in the intervention will use a mobile application that plays calming music personalized for sleep enhancement, relaxation techniques and nighttime routine guidance.

Outcome Measures

Primary Outcome Measures

  1. Acceptability [4 weeks]

    At least 80% of the dyads will find the intervention acceptable

Secondary Outcome Measures

  1. PLWD Objective Sleep Outcomes [1 month, 3 months]

    Compared to PLWD in the sleep education control group, PLWD in the CoMPoSER intervention will experience improved insomnia symptoms of sleep latency, sleep efficiency, wake after sleep onset, total sleep time measured via sleep diary and actigraphy.

  2. PLWD Subjective Sleep Outcomes [1 month, 3 months]

    Compared to PLWD in the sleep education control group, PLWD in the CoMPoSER intervention will experience improved sleep quality via self-report. The Pittsburgh Sleep Quality Index (PSQI) will be used to measure sleep quality. In scoring the PSQI, seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality.

  3. Caregiver Stress Outcome [1 month, 3 months]

    Compared to caregivers in the sleep education control group, caregivers in the CoMPoSER intervention will experience less perceived stress. The Perceived Stress Scale (PSS) will be used to assess perceived stress among caregivers. The PSS has 10 items. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.

  4. Caregiver Wellbeing Outcome (Burden) [1 month, 3 months]

    Compared to caregivers in the sleep education control group, caregivers in the CoMPoSER intervention will experience improved wellbeing (less burden). The Zarit Burden Scale will be used to assess caregiver wellbeing. The ZBI consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden/worse wellbeing.

  5. Caregiver Wellbeing Outcome (Depression) [1 month, 3 months]

    Compared to caregivers in the sleep education control group, caregivers in the CoMPoSER intervention will experience improved wellbeing (less depression). The Patient Health Questionnaire (PHQ-9) will be used to assess caregiver wellbeing (depression). The PHQ-9 consists of 9 items rated on a 4-point Likert scale that ranges from 0 (not at all) to 4 (nearly every day) with the sum of scores ranging between 0-27. Higher scores indicate greater depression/worse wellbeing.

  6. Stress Change [1 month]

    Changes in diurnal salivary cortisol from baseline to 1 month will mediate the effect of CoMPoSER on insomnia symptoms in PLWD.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria for persons living with dementia (PLWD):
  • Age 60 and above

  • Existing physician diagnosis of dementia or self-reported memory impairment and Clinical Dementia Rating Scale score of greater than 0.5,

  • Score of >10 on the Insomnia Severity Index

  • Stable dose of psychotropic medications

  • Agreeing to wear an actiwatch for the duration of the study

PLWD Exclusion Criteria:
  • Hearing impairment

  • Planned transition to a residential or institutional care facility in 3 months

  • Presence of extrapyramidal symptoms or acute sleep disruption

  • Bed bound

  • Living in an alternative home setting (such as Assisted Living Community)

Informal caregivers inclusion criteria:
  • Age 18 and above.

  • Providing at least 4 hours of daily care

  • Living with PLWD

  • Able to read and communicate in English

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Rutgers, The State University of New Jersey
  • National Institute on Aging (NIA)

Investigators

  • Principal Investigator: Darina Petrovsky, Rutgers University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Darina Petrovsky, PhD, RN, Assistant Professor, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT06088810
Other Study ID Numbers:
  • Pro2023000592
  • 1K23AG073618-01
First Posted:
Oct 18, 2023
Last Update Posted:
Oct 18, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Darina Petrovsky, PhD, RN, Assistant Professor, Rutgers, The State University of New Jersey
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2023